284461-73-0 Sorafenib AKSci J10391
 
 
Loading Please Wait...
  J10391    AKSci Reference Standard
Sorafenib, 99% (HPLC), powder
 
BAY 43-9006
Nexavar
Sorafenibum
IDENTITY
CAS Number:284461-73-0
MDL Number:MFCD06411450
MF:C21H16ClF3N4O3
MW:464.82
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99% (HPLC), powder
Physical Form (at 20°C):Solid
Melting Point:202-211°C
Density:1.5
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO: 127mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Antineoplastic Agent; Protein Kinase Inhibitor
Form:Free Base

REVIEW
 Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis. Sorafenib inhibited tumor growth and angiogenesis of human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice.

REFERENCES
[1]Keating GM, Santoro A (2009). Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69 (2): 223-40. doi:10.2165/00003495-200969020-00006. PMID 19228077.
[2] Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M (January 2009). CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28 (1): 85-94. doi:10.1038/onc.2008.362. PMC 2898184. PMID 18794803.
[3] Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (October 2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7 (10): 3129-40. doi:10.1158/1535-7163.MCT-08-0013. PMID 18852116.
[4] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (January 2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356 (2): 125-34. doi:10.1056/NEJMoa060655. PMID 17215530.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Danger

Hazard Statements
H360; H362; H372; H410

Precautionary Statements
P201; P202; P2610; P263; P264; P270; P273; P280; P308+P313; P391; P405; P501

Current as of April 20, 2024

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > Protein Kinase Inhibitors


PubChem